Sirona Dental Systems — Q1 2014 Earnings Presentation
18 slides from Sirona Dental Systems's earnings presentation, Feb 7, 2014
Slide 1: Sirona – The Dental Company: First Quarter 2014 Earnings Presentation
Sirona – The Dental Company First Quarter 2014 Earnings Presentation February 7, 2014
Slide 2: Safe Harbor Statement / Additional Information
First Quarter 2014 Earnings Presentation Safe Harbor Statement / Additional Information This conference call contains forward-looking information about Sirona Dental Systems, Inc.’s financial results, guidance and estimates, business prospects, and products and services that involve substantial risk
Slide 3: First Quarter 2014 Performance Summary
First Quarter 2014 Performance Summary 1Q14 constant currency revenue growth of 6.3%, with: Instruments up 18.1%, cc CAD/CAM up 7.6%, cc Imaging up 7.0%, cc Treatment Centers down 3.0%, cc Revenue growth was driven by the U.S. and international markets, despite a decline in Germany. U.S. revenues gr
Slide 4: Overview
First Quarter 2014 Earnings Presentation Overview Revenue Record revenues of $298.7 million, up 9.7% compared (US$ in millions) to prior year, or up 6.3% constant currency, with a record quarter in Imaging and Instruments. United States revenues increased 12.2%. Growth in the U.S. was driven by stre
Slide 5: CAD/CAM Segment
First Quarter 2014 Earnings Presentation CAD/CAM Segment CAD/CAM Revenue Segment Gross Profit (US$ in millions) (US$ in millions) Revenue Growth Segment Gross Profit Margin Reported +10.7% 1Q13 70.7% Currency (Euro/$) - 2.9% 1Q14 69.3% Constant Currency +7.6% Change -140 bps Page 5
Slide 6: CAD/CAM Segment
First Quarter 2014 Earnings Presentation CAD/CAM Segment Revenues of $105.8 million, up 10.7%, or up 7.6% cc. CAD/CAM segment revenues benefited from strength across the entire portfolio. In chair side, growth was driven by both upgrades and new user sales. CAD/CAM segment gross profit margin decrea
Slide 7: Imaging Segment
First Quarter 2014 Earnings Presentation Imaging Segment Imaging Revenue Segment Gross Profit (US$ in millions) (US$ in millions) Revenue Growth Segment Gross Profit Margin Reported +9.2% 1Q13 60.2% Currency (Euro/$) - 2.2% 1Q14 58.1% Constant Currency +7.0% Change -210 bps Page 7
Slide 8: Imaging Segment
First Quarter 2014 Earnings Presentation Imaging Segment Record segment revenues of $105.8 million, up 9.2%, or up 7.0% cc. Sales growth was driven by strength in intra-oral and the Orthophos XG product line. Gross profit margin decreased 210 bps mostly impacted by the extra oral product mix and tar
Slide 9: Treatment Centers
First Quarter 2014 Earnings Presentation Treatment Centers Treatment Center Revenue Segment Gross Profit (US$ in millions) (US$ in millions) Revenue Growth Segment Gross Profit Margin Reported 1.7% 1Q13 39.6% Currency (Euro/$) - 4.7% 1Q14 39.0% Constant currency - 3.0% Change -60 bps Page 9
Slide 10: Treatment Centers
First Quarter 2014 Earnings Presentation Treatment Centers Revenues of $54.4 million, up 1.7%, but down 3.0% cc, due to a challenging comparable. Last year’s Q1 Treatment Centers grew 8.4% cc and benefited from the start of the M1+ anniversary sale. International non-European markets led growth. Gro
Slide 11: Instruments
First Quarter 2014 Earnings Presentation Instruments Instruments Revenue Segment Gross Profit (US$ in millions) (US$ in millions) Revenue Growth Segment Gross Profit Margin Reported +23.9% 1Q13 46.2% Currency (Euro/$) - 5.8% 1Q14 41.3% Constant Currency +18.1% Change -490 bps Page 11
Slide 12: Instruments
First Quarter 2014 Earnings Presentation Instruments Record revenues of $32.7 million, up 23.9%, or up 18.1% cc. Revenue growth was driven primarily by non-European international markets. Gross profit margin decrease was primarily due to the strong growth in project business and continued costs asso
Slide 13: Guidance
First Quarter 2014 Earnings Presentation Guidance Guidance Constant currency revenue growth of 4% to 6% Non-GAAP Adjusted EPS in the range of $3.60 to $3.70 Key Inputs Overall segment gross margin to be similar to prior year’s level SG&A to be between 29% to 30% of sales R&D to be between 5% to 6% o
Slide 14: Conclusion
First Quarter 2014 Earnings Presentation Conclusion Solid business momentum continues. Commitment to innovation Comprehensive, market leading product portfolio Global sales and service infrastructure Geographic diversification Best-in-class distribution network Strong financial position Completed le
Slide 15: Operating Performance
First Quarter 2014 Earnings Presentation Operating Performance 1Q14 1Q13 % chg. Revenue $ 298,726 $ 272,404 9.7% Cost of sales 135,995 120,533 12.8% Gross profit 162,731 151,871 7.2% Selling, general and administrative expense 88,057 85,853 2.6% Research and development 15,118 14,095 7.3% Other oper
Slide 16: Reconciliation of GAAP EPS to Non-GAAP Adjusted EPS
Reconciliation of GAAP EPS to Non-GAAP Adjusted EPS Three months ended December 31, 2013 Per Diluted Pre Tax Tax Impact* After Tax Share $'000s, except per share amount GAAP net income attributable to Sirona Dental Systems, Inc. shareholders $ 44,171 $ 0.79 Adjustments Amortization and depreciation
Slide 17: Reconciliation of GAAP to Non-GAAP Adjusted EPS Guidance
Reconciliation of GAAP to Non-GAAP Adjusted EPS Guidance Low End of Guidance Per Diluted Pre-Tax Tax Impact After Tax Share $ millions, except per share amount GAAP net income attributable to Sirona Dental Systems, Inc. shareholders $ 174 $ 3.10 Adjustments Amortization and depreciation expense resu
Slide 18: Non-GAAP Measures Disclosure
Non-GAAP Measures Disclosure To supplement our consolidated financial statements and our business outlook, we use the following non-GAAP financial measures: (i) non-GAAP adjusted net income, and (ii) non-GAAP adjusted earnings per diluted share, which exclude, as applicable, amortization and depreci
Sirona Dental Systems — Q1 2014 Earnings Presentation on 6ix